Wisconsin Alumni Research Foundation

Technology

Novel Small Molecule SIRT6 Activators/Inhibitors

The epigenetic modifier SIRT6 is of the sirtuin class of proteins. In transgenic mice, increased SIRT6 expression lowers LDL and triglyceride levels, improves glucose tolerance and increases mitochond...
Learn More
John Denu, Weiping Tang | P160306US01

Technology

Inhibiting Metadherin/SND1 Interaction to Treat Cancer

Metadherin (MTDH; also called AEG1 or LYRIC) is a pro-metastasis gene implicated in many types of cancer. The gene is overexpressed in more than 40 percent of primary tumors and is linked to breast ca...
Learn More
Yongna Xing, Liling Wan, Yibin Kang, Feng Guo | P140424US02

Technology

Increasing Red Blood Cell Production

Maintaining an adequate supply of oxygen to tissue is necessary for survival. The oxygen-carrying capacity of blood is governed by the concentration of red blood cells (erythrocytes). It is critical t...
Learn More
Emery Bresnick, Yoon A Kang, Skye McIver | P130326US02

Technology

Treating Iron Overload with Block Copolymers

Iron overload or hemochromatosis is a disease marked by an accumulation of iron in the blood. It typically occurs in subjects (e.g., anemia patients) receiving chronic infusions of red blood cells. Th...
Learn More
May Xiong, Zhi Liu, Yan Wang | P140395US02

Technology

Provoking Anti-Tumor Immune Response with Rhamnose

One promising approach to cancer treatment is to leverage the immune system. Specifically, tumors can be ‘tagged’ with foreign antigens that attract the body’s defensive antibodies. The antibodi...
Learn More
Laura Kiessling, Rachael Sheridan, Jonathan Hudon | P120290US02

Technology

Vitamin D Analogs for Treating Bone Cancers and Diseases

The hormonally active form of vitamin D, known as calcitriol or 1,25 dihydroxyvitamin D3, has shown promise for treating diseases ranging from osteoporosis to cancer to psoriasis. However, the hormone...
Learn More
Hector DeLuca, Margaret Clagett-Dame, Lori Plum, Izabela Sibilska-Kaminski, Rafal Sicinski | P100358US03

Technology

Prostate Cancer and Melanoma Screening

Almost 200,000 men in the United States develop prostate cancer each year. More than 60,000 people develop melanoma. Early diagnosis is key to survival because the best treatment and prognosis for the...
Learn More
Douglas McNeel, Edward Dunphy, Jason Dubovsky, Luke Hoeppner | P06004US

Technology

Cytotoxic Ribonuclease Variants

Ribonucleases are enzymes that catalyze the degradation of RNA. Levels of RNase activity are controlled in vivo by a ribonuclease inhibitor (RI), which binds strongly to an RNase to completely inhibit...
Learn More
Ronald Raines, George Phillips, R. Jeremy Johnson, Jason McCoy | P05341US

Technology

Cytotoxic Ribonuclease Variants

Ribonucleases are enzymes that catalyze the degradation of RNA. Levels of RNase activity are controlled in vivo by a ribonuclease inhibitor (RI), which binds strongly to an RNase to completely inhibit...
Learn More
Ronald Raines, Julie Mitchell, Thomas Rutkoski | P04427US

WARF